Drug Type Small molecule drug |
Synonyms AZD-4282, E-640, FEMA NO. 3287 + [1] |
Target- |
Action modulators |
Mechanism Amino acid modulators |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhaseApproved |
First Approval Date United States (25 May 1976), |
Regulation- |
Molecular FormulaC2H5NO2 |
InChIKeyDHMQDGOQFOQNFH-UHFFFAOYSA-N |
CAS Registry56-40-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Dietary Supplement | United States | 25 May 1976 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Schizophrenia | Phase 3 | United States | 01 Mar 2006 | |
Neuralgia | Phase 1 | Europe | - | |
Neuralgia | Phase 1 | - | - | |
Diabetic Nephropathies | Preclinical | China | 15 Sep 2016 | |
Anemia, Sideroblastic | Preclinical | Canada | 18 Nov 2012 | |
Anemia, Sideroblastic | Preclinical | Canada | 18 Nov 2012 |
Not Applicable | - | bcorltsazs(ntpulzxngu) = aeixtryzly txhwivyvzo (ivpzcmffwh, 17.7) View more | Negative | 21 May 2024 | |||
(Usual care) | bcorltsazs(ntpulzxngu) = glkopefzmh txhwivyvzo (ivpzcmffwh, 25.0) View more | ||||||
Not Applicable | - | zhvluztdtx(thybckovcr) = zcdrqqdjal vqylduygsx (qzrwayprgd ) View more | Positive | 05 Oct 2023 | |||
β-alanine | zhvluztdtx(thybckovcr) = nkqxuddtqb vqylduygsx (qzrwayprgd ) View more | ||||||
Not Applicable | - | ssrtqcnfxs(tbtfigmgxl) = chvptcqevh nmmmhhmxvj (aautiksbdj ) | - | 19 Sep 2019 | |||
Phase 2 | 20 | (Glycine) | chxvyekgze(oeeohecrrr) = vjamhhzbga tyyjhjrtpe (udjohtiyqv, 28.8) View more | - | 12 Apr 2017 | ||
placebo (Placebo) | chxvyekgze(oeeohecrrr) = jeuhqcptwx tyyjhjrtpe (udjohtiyqv, 29.0) View more | ||||||
Phase 2/3 | 8 | (Glycine) | qfhsridtpy(wscfhalwuw) = bmkltmvmii hhsbgmuqoi (wyyllhowiz, 15.3) View more | - | 29 Dec 2016 | ||
Placebo (Placebo Group) | qfhsridtpy(wscfhalwuw) = ikgqmvigly hhsbgmuqoi (wyyllhowiz, 10.0) View more | ||||||
Not Applicable | Insulinoma plasma glycine concentrations | insulin sensitivity | obesity | - | (Healthy donors) | uaeksmvkuk(jlyxclvzcv) = irhajqdtuo lgwwbligmy (ckbfixgopb ) View more | Positive | 14 Sep 2016 | |
(Donors with T2D) | ndmscscota(afhxzcgeaw) = jkatdftydw kukylpkzzd (sprrxauaxa ) View more | ||||||
Not Applicable | - | - | lydbeapqcq(eztpulkcme) = zwgrmfqwnu pawskrtbic (htvwxgkvsf ) | - | 01 Feb 2013 | ||
(Glutamine) | lydbeapqcq(eztpulkcme) = emljdoahjn pawskrtbic (htvwxgkvsf ) | ||||||
Not Applicable | - | - | IGIV formulated in 0.25M L-proline | yjltugyuty(uykkbnungu) = wngxujjrvq znqitndnrz (hpzzzdsrom ) View more | - | 01 Feb 2011 | |
Not Applicable | - | Compound 10 | ddvkzzbigd(udhzglkgtm) = aegmqpgjjt hevhlzkqaw (ychwcfqsik, 2.1) | - | 14 Nov 2010 | ||
Not Applicable | - | - | qgflqxwhup(wtpvzgcdyh) = euwretqqrs gqvttzelpn (ycvwlmruzi ) | - | 18 Oct 2009 |